Rainbow Children's Medicare Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹16,071 Cr
- Book Value
- ₹162
- Stock P/E
- 56.1
- Dividend Yield
- 0.22%
- ROE
- 15.9%
- ROCE
- 17.4%
- PEG Ratio
- 1.27
- EV/EBITDA
- 27.7
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Technical snapshot
EOD ·Rainbow Children's Medicare Ltd closed at ₹1,461.80 on 19 August 2026, up 0.2% on the day, 0.5% below its 50-day average, 9.2% below its 52-week high, with volume at 0.42× its 20-session average.
- RSI 14
- 44.0
- vs 50-day SMA
- -0.5%
- vs 200-day SMA
- +10.7%
- From 52-week high
- -9.2%
- Relative volume
- 0.42×
- 20-day return
- -1.9%
End-of-day prices from exchange-published files (NSE/BSE bhavcopy), updated after market close. Descriptive statistics, not investment advice.
Rainbow Children’s Medicare share price today
Rainbow Children’s Medicare (NSE: RAINBOW) is India’s only listed pediatric and perinatal hospital chain — children’s intensive care, neonatal ICUs, pediatric specialties and women’s health, delivered hub-and-spoke across Hyderabad, Bengaluru, Chennai, Delhi and beyond. The specialty focus is the moat: pediatric intensivists and neonatologists are scarce, parents don’t comparison-shop a sick child, and referral networks route the hardest cases to the specialist with the NICU beds.
Growth reflects both demand and expansion: 44% five-year profit CAGR with 31.6% operating margins. The headline D/E of 0.54 mainly reflects capitalised hospital leases rather than borrowing stress. At 56.1× with a PEG of 1.27, specialty scarcity is already well recognised.
The specialist premium
General hospitals treat children; Rainbow is built for them — 24/7 pediatric emergency, child-sized everything, and the clinical outcomes that come from volume concentration in rare conditions. Birth-rate anxiety misreads the thesis: pediatric tertiary care is penetration-driven (insurance, urbanisation, parental spending), not birth-count-driven, and women’s-health services (fertility, high-risk obstetrics) feed the pediatric funnel by design. New units in north India climb their J-curves on schedule.
What matters next: new-hospital ramp trajectories, clinician retention (the scarce input), payor-mix evolution, and any regulatory pricing intervention across private healthcare.
The numbers
Financial snapshot — 5 August 2026
| Metric | Value |
|---|---|
| Market cap | ₹16,071 Cr |
| P/E (TTM) | 56.1 |
| EV/EBITDA | 27.7 |
| Operating margin | 31.6% |
| ROE / ROCE | 15.9% / 17.4% |
| Debt to equity | 0.54 (capitalised leases) |
| Sales CAGR (5y) | 21.2% |
| Profit CAGR (5y) | 44.0% |
| Promoter holding | 49.8% |
| EPS (TTM) | ₹28.15 |
Rainbow Children’s share price target 2026 to 2030
EPS base ₹28.15 (TTM). Bear: ramps slow, pricing scrutiny lands — 12% growth, multiple at 32×. Base: the network compounds as new units mature — 18% growth at 45×. Bull: specialty scarcity premium extends nationally — 24% growth at 58×.
From ₹1,579, the base case is ≈ +84% over four and a half years, while the bear case is flat (+1%). That spread depends on new hospitals climbing their J-curves without sacrificing clinician depth or cash returns.
What supports the case
- The only listed pure-play on pediatric care — scarcity in listing and specialty both.
- Referral moats: the hardest cases route to the deepest NICU bench.
- 44% profit CAGR as new hospitals climb their J-curves.
- Women’s-health services feed the pediatric funnel structurally.
- PEG 1.27 for specialty-hospital growth is reasonable against the sector.
The risks: clinician scarcity cuts both ways (retention is existential), healthcare pricing is a standing political target, and lease-heavy expansion needs each ramp to perform.
What to weigh at the current price
The tension is whether new hospitals can mature on schedule before clinician scarcity, lease commitments or pricing scrutiny expose how much growth 56.1× earnings already assumes.
FAQ
What is the Rainbow Children’s share price target for 2030? The table above sets out bear, base and bull scenarios for each year to 2030. They are valuation sensitivities, not promised prices.
Doesn’t a falling birth rate hurt Rainbow? Volume in pediatric tertiary care comes from penetration — insurance coverage, urbanisation, willingness to pay for specialists — which is rising far faster than birth counts are drifting.
Why is D/E of 0.54 considered manageable? Accounting standards capitalise long hospital leases as debt. Rainbow’s actual borrowings are modest; the ratio reads worse than the balance sheet lives.
When are Rainbow’s next results? Check the results calendar and confirm the announced date in the relevant exchange filing.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.